Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist ...

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing ...

By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.

UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...

Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending ...

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a ...

Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...

While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 ...

BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

Nusano will bring a massive new radioisotope facility in Salt Lake City online by the end of the year, establishing a supply ...